- Hemogenyx Pharmaceuticals said it had filed a patent covering new methods to transplant bone marrow and treat blood cancers.

The new patent covered a method of application of bi-specific antibodies (CDX) for conditioning patients for bone marrow transplantation and composition matter (sequences) of newly-discovered monoclonal antibodies against a target protein expressed on the surface of hematopoietic stem cells/hematopoietic progenitors and a number of leukemias, such as acute myeloid leukemia, the company said.

The antibody being developed, CDX, should, if successful, provide a new, effective and safe method of conditioning patients for bone marrow transplants, and had the potential to be a superior pharmaceutical for the treatment of blood cancers, for which survival rates are currently very poor,' the company said.

'Filing this patent is an important development and further solidifies Hemogenyx's leadership position in the development of new methods of bone marrow transplantation and treatments for blood cancers such as AML, acute lymphoblastic leukemia and possibly others,' it added.

Story provided by